Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS COV2) caused
Coronavirus disease 2019 (COVID-19), which was first recorded in Wuhan,
China in December 2019 [1]. COVID-19 is primarily a respiratory
infection, but it can also affect multiple organ systems including
cardiac, neurological, gastrointestinal and renal systems [2].
Viremia and cytokine storm are common in COVID-19 especially in
immune-compromised patients, and that may activate the coagulation
cascade which causes thrombotic complications and coagulopathies
including cardiac thrombosis and disseminated intravascular coagulopathy
[3].
D-dimer is a fibrin degradation product, which is used as a biomarker
for thrombotic disorders. It is considered normal with values less than
0.5 μg/mL, and the level of D-dimer rises in severe community-acquired
pneumonia, it is also used as an initial screening test to diagnose
patients who have signs, or symptoms suggestive of venous
thromboembolism [4]. D-dimer is detectable in patients with deep
venous thrombosis (DVT), as it is a marker of endogenous fibrinolysis.
Following the outbreak of the COVID-19 pandemic, D-dimer has been
identified as a potential indicator for its prognosis in COVID-19
patients. [5].